Hi, I am Urban from Kieger. Welcome to our chart of the months.
Shares of GLP-1 producers have been surging with the data release of Novo Nordisk’s SELECT trial. The trial showed
that patients taking GLP-1 can loose 15-20% body weight and reduce cardiovascular risk.
First this is amazing news for patients, but then if you think a bit further, being able to treat obesity could have huge implications. So investors quickly implied that with less obese people there will be less patients with sleep apnea or diabetes and shares of companies active in these two areas collapsed.
We think it is too early to tell, as many other factors play into e.g. developing diabetes or sleep apnea.
Nevertheless, it is amazing to see what innovation can do and how much we still have to discover. Stay tuned
